ONCOLOGY Vol 38, Issue 9

Experts in gastrointestinal cancer focus on frontline therapy options for patients with pancreatic cancer.

Experts in multiple myeloma discussed optimal dosing strategies for bispecific antibodies for patients with relapsed/refractory multiple myeloma.

Laura Bucher-Bailey, PharmD, discussed the approval of tisotumab vedotin-tftv for patients with recurrent or metastatic cervical cancer who have had progression after chemotherapy.

Carl He, MD, explores the barriers to adherence to treatment recommendations offered by the multidisciplinary team meeting in cancer care.

Nausheen Ahmed, MD, discusses the FDA REMS mandate to help assess toxicity in patients receiving CAR T-cell therapy.

Julie M. Vose, MD, MBA, reviews the rising cancer diagnoses that are estimated to impact 2 million people in 2024.